HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra Found In Herbal Imports From Firms In China, South Korea

This article was originally published in The Rose Sheet

Executive Summary

FDA latest import alerts updates also include numerous firms in the Bahamas, China and India shipping supplements and personal care and cosmetic products labeled with drug claims and a Malaysian firm that is not compliant with supplement good manufacturing practices regulations.

You may also be interested in...



US Fish Oil Supplement Export Certification Program Continued 90 Days With Home TBD

NOAA Seafood Inspections Program had planned 1 May end to export certifications for fish oil supplements before granting 90-day extension as it talks with FDA about administering the program.

More Ephedra Found, Sibutramine Crime In Texas: Health And Wellness Industry News

MusclMasster recalls Al-Er-G after FDA officials discovered during a recent inspection it contained ephedra. The use of sibutramine in products marketed as supplements led to a Texas man's conviction on a criminal count of possessing a controlled substance.

FDA List Of Supplement Formulation Taboos Adds Ephedra-Like Ingredient

CFSAN warns seven companies about products marketed as supplements with labeling listing methylsynephrine as a dietary ingredient. The center also warned two of the firms their products contained other ingredients FDA previously began forcing off the market, DMAA and DMBA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel